By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Provista Diagnostics today announced it has entered into purchase agreements with institutional investors to raise $5 million in a Series A Preferred financing.

The funds will go mainly toward the completion of a confirmatory clinical trial and 510(k) submission to the US Food and Drug Administration of its breast cancer test. The remainder will be used to repay outstanding short-term debt obligations, the Phoenix-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.